

International Symposium - "New directions in Prostate Cancer Chemotherapy: Natural Products, Synthetic Compounds, NanoMedicinal Chemistry".

August 20-21, 2009, Bethesda, MD

Prostate cancer is the most common malignancy affecting men above 45-50 in the developed countries. In the United States more than 200,000 new cases of prostate cancer are registered annually. About 1 man in 5 will be diagnosed with prostate cancer during his lifetime, and 1 man in 33 will die of this disease. Initial stages of this disease are highly curable. Up until recently, late androgen-independent (hormone refractory) stage of prostate cancer was considered to be a very difficult to treat, if not terminal, condition. Emerging chemotherapy protocols provide a new hope for prostate cancer patients.

This symposium is intended to be an international forum aimed at sharing new ideas and directions in the area of prostate cancer chemotherapy. The emphasis will be put on emerging areas of research, such as the use of NanoMedicinal Chemistry, novel small therapeutic molecules and natural products, supercomputer chemistry, and others. Specific attention will be given to identification of the US Government funding opportunities related to this effort.

The Symposium will be held in conjunction with the 238<sup>th</sup> ACS National Meeting at the NIH main campus in Bethesda, MD, August 20 and 21, 2009. It is sponsored in part by the NIH Fogarty International Center and by the DOE GIPP Discovery Chemistry Project.

Deadline for submission of the ACS-style 150-word e-abstracts directly to the Symposium organizers is July 3, 2009.

Please refer further questions and correspondence to the Symposium organizers:

Dr. Marya Levintova  
Fogarty International Center  
National Institutes of Health  
[levintovam@mail.nih.gov](mailto:levintovam@mail.nih.gov)

Dr. Andrei Gakh  
Oak Ridge National Laboratory  
[gakhaa@ornl.gov](mailto:gakhaa@ornl.gov)